SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Irène Joliot-Curie

PatientIrène Joliot-Curie
Date of birth1968-09-12
IdentifiersMRN HR-RB003-SYN; SSN (made up) 000-03-8841
Document date2026-10-30
AuthorSolène Marchand-Ellis, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Count recovery, response assessment, cycle 2, transplant planning, and her dose records. [S]

History of Present Illness

Mrs. Joliot-Curie returns on day 33, eleven days after venetoclax was stopped. She feels stronger, walks for half an hour, and has begun reading papers again. She has had no fever or bleeding. Her posaconazole trough level, drawn three days ago, was in the target range. The transplant center reports that the unrelated donor search has found two fully matched donors. Her employer's radiation safety office has acknowledged her request and is assembling her dose records, including the bioassay from the laboratory accident. [S]

ElementDetail
CycleDay 33 of cycle 1; venetoclax stopped on day 22
SymptomsStronger; no fever or bleeding
TransplantTwo fully matched unrelated donors identified
Dose recordsRequest acknowledged; records being assembled

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving; no fever or night sweats
RespiratoryPositiveBreathless on stairs, as before
GastrointestinalNegativeEating well; bowels regular
IntegumentaryNegativeNo bruises
PsychiatricNegativeMood steady; PHQ-9 6

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycleOnce daily on days 1 to 7 of each 28-day cycleSubcutaneous route2026-09-28activeS
Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole)Ramp-up, then two tablets daily with the 50 mg tablet, with food and waterOral route2026-09-28 to 2026-10-19completedS
Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day)One tablet daily from day 3, with food and waterOral route2026-09-28 to 2026-10-19completedS
Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic300 mg twice on day 1, then 300 mg once daily with foodOral route2026-09-28activeS
Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxisOne tablet twice dailyOral route2026-09-28activeS
Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5One tablet daily during profound neutropeniaOral route2026-09-28 to 2026-10-30completedS
Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1One tablet dailyOral route2026-09-28 to 2026-10-19completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route2026-10-08activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g once daily, held for loose stoolsOral route2026-10-08activeS
Sennosides 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route2026-10-08 to 2026-10-19completedS
Potassium chloride 20 mEq extended-release tablet, one tablet twice daily for three daysOne tablet twice daily for three daysOral route2026-10-08 to 2026-10-11completedS
Venetoclax 10 mg oral tablet, cycle 2: two tablets daily with the 50 mg tablet (70 mg a day, the dose with posaconazole) on days 1 to 21Two tablets daily on days 1 to 21, with food and waterOral route2026-10-30activeS
Venetoclax 50 mg oral tablet, cycle 2: one tablet daily with two 10 mg tablets (70 mg a day) on days 1 to 21One tablet daily on days 1 to 21, with food and waterOral route2026-10-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-30Body height163cmS
2026-10-30Body weight53.6kgS
2026-10-30Body mass index (BMI) [Ratio]20.2kg/m2S
2026-10-30Systolic blood pressure118mm[Hg]S
2026-10-30Diastolic blood pressure72mm[Hg]S
2026-10-30Heart rate84/minS
2026-10-30Respiratory rate16/minS
2026-10-30Body temperature36.8CelS
2026-10-30Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-30Leukocytes [#/volume] in Blood by Automated count2.210*3/uL4-11 10*3/uLLowS
2026-10-30Neutrophils [#/volume] in Blood by Automated count0.910*3/uL1.5-7.5 10*3/uLLowS
2026-10-30Hemoglobin [Mass/volume] in Blood9.6g/dL12-15.5 g/dLLowS
2026-10-30Platelets [#/volume] in Blood by Automated count8810*3/uL150-400 10*3/uLLowS
2026-10-30Blasts/Leukocytes in Blood by Manual count0%None seen normallyNormalS
2026-10-30Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-30Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-10-30Creatinine [Mass/volume] in Serum or Plasma0.81mg/dL0.57-1 mg/dLNormalS
2026-10-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-30Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-35 U/LNormalS
2026-10-30ECOG Performance Status score1{score}S
2026-10-30Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S

Physical Exam

Vital signs recorded on 2026-10-30; see the Vital Signs section. [S]

SystemFinding
GeneralBrighter; weight 53.6 kg; ECOG 1
MouthNo ulcers or thrush
RespiratoryFine crackles at the right apex, unchanged
SkinNo bruises or petechiae
AbdomenNo enlarged liver or spleen

Problems

ProblemClinical statusVerificationCodeProvenance
Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review bookedresolvedconfirmed D61.818S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D).
Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemiaactiveconfirmed C92.00S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented.
Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years agoactiveconfirmed Z57.1S — Synthetic modern coding of her documented occupational exposure.
Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active diseaseactiveconfirmed Z86.11S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic.
Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive inductionactiveconfirmed R94.2S — Synthetic finding on pre-treatment testing.
Nausea with vomiting and constipation on day 11 of cycle 1 of azacitidine with venetoclax, without fever, with mild low potassium; managed as an outpatient; resolvedresolvedconfirmed R11.2S — Synthetic treatment side effect; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with differential and smearAt diagnosis; two to three times a week during induction; before each cycleCompleted todayWhite cells 2.2, neutrophils 0.9, hemoglobin 9.6 g/dL, platelets 88 x10^3/uL; no blasts: ELN 2022 complete remission with partial hematologic recovery
LaboratoryBone marrow: morphology, flow cytometry, cytogenetics, molecular panelAt diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning requireDueMeasurable residual disease marrow after cycle 2
LaboratoryChemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver testsAt diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycleCompleted todaySodium 139, potassium 4.2 mmol/L; creatinine 0.81 mg/dL, eGFR 84; ALT 28 U/L
Medication safetyAzole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough levelAt start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drugCompleted todayTrough level in the target range three days ago; liver tests normal; venetoclax kept at 70 mg
SurveyPerformance statusBefore each cycleCompleted todayECOG 1, from 2 at the start of treatment
Medication safetyTransfusion support: thresholds, irradiated and leukoreduced productsAt each blood countCompleted todayNo transfusion needed since day 11
Self-managementInfection prophylaxis and the fever planThroughout neutropeniaCompleted todayLevofloxacin stopped; posaconazole and acyclovir continue through cycle 2; fever plan unchanged
ReferralHLA typing and allogeneic transplant evaluationDuring remissionCompleted todayTwo matched unrelated donors found; reduced-intensity transplant planned after two to three more cycles
ReferralSpecialist palliative care: symptoms, prognosis, goals and valuesAt every visitCompleted todayPalliative care continues alongside treatment; goals recorded at the preventive visit
SurveyDistress, depression and anxiety screeningAt each phase of treatmentCompleted todayPHQ-9 6, mild
Self-managementOccupational exposure history and dose recordsUntil the records are receivedDueRequest acknowledged; records being assembled

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022); DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026); 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Cycle 2 as planned, with twice-weekly blood counts. Marrow after cycle 2. Transplant center visit in two weeks. Palliative care at each visit. Emergency department at once for a temperature of 38.0 °C or more. [S]